Overview

Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness

Status:
Recruiting
Trial end date:
2025-04-30
Target enrollment:
0
Participant gender:
All
Summary
An open label study to investigate the safety and efficacy of tradipitant in participants affected by motion sickness during travel
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Vanda Pharmaceuticals
Criteria
Inclusion Criteria:

- History of Motion Sickness

- Age 18-75

Exclusion Criteria:

- Nausea-inducing disorder other than motion sickness

- BMI > 40

- History of intolerance and/or hypersensitivity to Neurokinin-1 Receptor antagonists